Studies of the antithrombotic effects of dextran 40 following microarterial trauma.
The effects of dextran 40 on platelet function and thrombus formation have been studied in vivo in arteries of the rabbit ear. Intra-aortic infusions of 32P-labelled platelets were followed by infusions of 1.7 g dextran 40 in 17 ml saline/kg b w. Treated and untreated groups were studied using as trauma either end-to-end anastomosis or arteriotomy (7 mm)/intimectomy (5 mm). After restoring blood flow, bleeding times at the sites of anastomosis and arteriotomy/intimectomy were recorded. Accumulations of labelled platelets were followed in vivo for 2 hours, after which patencies were determined and amounts of red thrombotic material evaluated. In a separate series of measurements, haematocrit levels after dextran infusion were studied. Nearly all vessels in the end-to-end anastomosis groups were patent. In the arteriotomy/intimectomy groups, there was a significant increase in patency following dextran infusion. Dextran infusion did not alter platelet accumulation following end-to-end anastomosis, but following arteriotomy/intimectomy median values were somewhat reduced. Its antithrombotic effects must therefore arise mainly at stages of thrombus formation subsequent to platelet deposition.
Salemark
L
L
Department of Experimental Research, Malmö General Hospital, Sweden.
Wieslander
J B
JB
Dougan
P
P
Arnljots
B
B
D000714:Anastomosis, Surgical; D000818:Animals; D001158:Arteries / Q000601:surgery* / Q000648:ultrastructure; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects; D003911:Dextrans / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006400:Hematocrit; D008297:Male; D008855:Microscopy, Electron, Scanning; D008866:Microsurgery; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011183:Postoperative Complications / Q000517:prevention & control; D011817:Rabbits; D014654:Vascular Patency / Q000187:drug effects
D003911:Dextrans; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors